Infliximab and nephrotic syndrome.
Infliximab is a chimeric tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody, which has been used extensively in patients with rheumatoid arthritis and inflammatory bowel disease. It also appears to be effective in other conditions such as psoriasis and ankylosing spondylitis. The major side effect of infliximab is infection. Renal complications are uncommon and not well recognized. This report describes a probable case of infliximab-induced membranous nephropathy.
Chin
George
G
Renal Unit, Sir Charles Gairdner Hospital, Nedlands. george.chin@phnt.swest.nhs.uk
Luxton
Grant
G
Harvey
Jennet M
JM
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D000069285:Infliximab; D007678:Kidney Glomerulus / Q000648:ultrastructure; D008854:Microscopy, Electron; D009404:Nephrotic Syndrome / Q000139:chemically induced* / Q000473:pathology; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab